Overview

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Status:
RECRUITING
Trial end date:
2030-02-22
Target enrollment:
Participant gender:
Summary
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Genentech, Inc.
Incyte Corporation
Treatments:
atezolizumab
Bevacizumab
pemigatinib